Extracts of Larix Leptolepis effectively augments the generation of tumor antigen-specific cytotoxic T lymphocytes via activation of dendritic cells in TLR-2 and TLR-4-dependent manner

Cellular Immunology

Volumn 276, Issue 1-2, 2012, Pages 153-161

  Koizumi, Shin ichi ^a   Masuko, Kazutaka ^a   Wakita, Daiko ^a   Tanaka, Sachi ^a   Mitamura, Rieko ^b   Kato, Yoshihiro ^c   Tabata, Homare ^c   Nakahara, Masahiro ^c   Kitamura, Hidemitsu ^a   Nishimura, Takashi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b FUJI WOMEN'S UNIVERSITY   (Japan)

^c Phytochemical Research Center   (Japan)

Author keywords

Adjuvant; Cancer immunotherapy; Cytotoxic T lymphocytes; Dendritic cells; Toll like receptor; Type 1 immunity

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; LARIX LEPTOLEPIS EXTRACT; PLANT EXTRACT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; LARIX; LARIX LEPTOLEPIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; LARIX; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

LARIX KAEMPFERI;

EID: 84863862334     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.05.002     Document Type: Article

References (64)

1. Brodsky I.E., Medzhitov R. Targeting of immune signalling networks by bacterial pathogens. Nat. Cell Biol. 2009, 11:521-526.
2. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
3. Narita Y., Wakita D., Ohkur T., Chamoto K., Nishimura T. Potential differentiation of tumor bearing mouse CD11b+Gr-1+ immature myeloid cells into both suppressor macrophages and immunostimulatory dendritic cells. Biomed. Res. 2009, 30:7-15.
4. Katona P., Katona-Apte J. The interaction between nutrition and infection. Clin. Infect. Dis. 2008, 46:1582-1588.
5. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 2004, 82:488-496.
6. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136:2348-2357.
7. Ikeda H., Chamoto K., Tsuji T., Suzuki Y., Wakita D., Takeshima T., Nishimura T. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004, 95:697-703.
8. Iijima N., Linehan M.M., Zamora M., Butkus D., Dunn R., Kehry M.R., Laufer T.M., Iwasaki A. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J. Exp. Med. 2008, 205:3041-3052.
9. Flynn J.L., Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 2001, 19:93-129.
10. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
11. Brown L.E., Kelso A. Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes. Immunol. Cell Biol. 2009, 87:300-308.
12. Badovinac V.P., Messingham K.A., Jabbari A., Haring J.S., Harty J.T. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 2005, 11:748-756.
13. Wakita D., Chamoto K., Zhang Y., Narita Y., Noguchi D., Ohnishi H., Iguchi T., Sakai T., Ikeda H., Nishimura T. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Int. Immunol. 2006, 18:425-434.
14. Hokey D.A., Larregina A.T., Erdos G., Watkins S.C., Falo L.D. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 2005, 65:10059-10067.
15. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
16. Villadangos J.A., Schnorrer P. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol. 2007, 7:543-555.
17. O'Neill D.W., Adams S., Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104:2235-2246.
18. Vyas J.M., Van der Veen A.G., Ploegh H.L. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 2008, 8:607-618.
19. Wilson N.S., Behrens G.M., Lundie R.J., Smith C.M., Waithman J., Young L., Forehan S.P., Mount A., Steptoe R.J., Shortman K.D., de Koning-Ward T.F., Belz G.T., Carbone F.R., Crabb B.S., Heath W.R., Villadangos J.A. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat. Immunol. 2006, 7:165-172.
20. Sato M., Chamoto K., Nishimura T. A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int. Immunol. 2003, 15:837-843.
21. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
22. Kitamura H., Morikawa H., Kamon H., Iguchi M., Hojyo S., Fukada T., Yamashita S., Kaisho T., Akira S., Murakami M., Hirano T. Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function. Nat. Immunol. 2006, 7:971-977.
23. Flesch I.E., Hess J.H., Huang S., Aguet M., Rothe J., Bluethmann H., Kaufmann S.H. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J. Exp. Med. 1995, 181:1615-1621.
24. Muller-Hermelink N., Braumuller H., Pichler B., Wieder T., Mailhammer R., Schaak K., Ghoreschi K., Yazdi A., Haubner R., Sander C.A., Mocikat R., Schwaiger M., Forster I., Huss R., Weber W.A., Kneilling M., Rocken M. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008, 13:507-518.
25. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680.
26. Pierre P., Turley S.J., Gatti E., Hull M., Meltzer J., Mirza A., Inaba K., Steinman R.M., Mellman I. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997, 388:787-792.
27. Sharpe A.H., Freeman G.J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2002, 2:116-126.
28. Toes R.E., Schoenberger S.P., van der Voort E.I., Offringa R., Melief C.J. CD40-CD40 Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin. Immunol. 1998, 10:443-448.
29. Acuto O., Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 2003, 3:939-951.
30. Liu Y., Saxena A., Zheng C., Carlsen S., Xiang J. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. J. Gene Med. 2004, 6:857-868.
31. Schendel D.J. Dendritic cell vaccine strategies for renal cell carcinoma. Expert Opin. Biol. Ther. 2007, 7:221-232.
32. Bhardwaj N., Seder R.A., Reddy A., Feldman M.V. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J. Clin. Invest. 1996, 98:715-722.
33. Markiewicz M.A., Wise E.L., Buchwald Z.S., Cheney E.E., Hansen T.H., Suri A., Cemerski S., Allen P.M., Shaw A.S. IL-12 enhances CTL synapse formation and induces self-reactivity. J. Immunol. 2009, 182:1351-1361.
34. Sabel M.S., Arora A., Su G., Mathiowitz E., Reineke J.J., Chang A.E. Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. Surgery 2007, 142:749-760.
35. Suzuki Y., Wakita D., Chamoto K., Narita Y., Tsuji T., Takeshima T., Gyobu H., Kawarada Y., Kondo S., Akira S., Katoh H., Ikeda H., Nishimura T. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res. 2004, 64:8754-8760.
36. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 2003, 3:133-146.
37. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
38. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., Prestwich G.D., Mascarenhas M.M., Garg H.G., Quinn D.A., Homer R.J., Goldstein D.R., Bucala R., Lee P.J., Medzhitov R., Noble P.W. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat. Med. 2005, 11:1173-1179.
39. Ohashi K., Burkart V., Flohe S., Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol. 2000, 164:558-561.
40. Vabulas R.M., Ahmad-Nejad P., da Costa C., Miethke T., Kirschning C.J., Hacker H., Wagner H. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem. 2001, 276:31332-31339.
41. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F.J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., Andre F., Delaloge S., Tursz T., Kroemer G., Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
42. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
43. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., Rayner K.J., Boyer L., Zhong R., Frazier W.A., Lacy-Hulbert A., El Khoury J., Golenbock D.T., Moore K.J. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat. Immunol. 2010, 11:155-161.
44. Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
45. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
46. Fitzgerald K.A., Chen Z.J. Sorting out Toll signals. Cell 2006, 125:834-836.
47. Uehori J., Matsumoto M., Tsuji S., Akazawa T., Takeuchi O., Akira S., Kawata T., Azuma I., Toyoshima K., Seya T. Simultaneous blocking of human Toll-like receptors 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin peptidoglycan. Infect. Immun. 2003, 71:4238-4249.
48. Akao Y., Ebihara T., Masuda H., Saeki Y., Akazawa T., Hazeki K., Hazeki O., Matsumoto M., Seya T. Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice. Cancer Sci. 2009, 100:1494-1501.
49. Santander S.P., Aoki M., Hernandez J.F., Pombo M., Moins-Teisserenc H., Mooney N., Fiorentino S. Galactomannan from Caesalpinia spinosa induces phenotypic and functional maturation of human dendritic cells. Int. Immunopharmacol. 2011, 11:652-660.
50. Hauer J., Anderer F.A. Mechanism of stimulation of human natural killer cytotoxicity by arabinogalactan from Larix occidentalis. Cancer Immunol. Immunother. 1993, 36:237-244.
51. Persat F., Noirey N., Diana J., Gariazzo M.J., Schmitt D., Picot S., Vincent C. Binding of live conidia of Aspergillus fumigatus activates in vitro-generated human Langerhans cells via a lectin of galactomannan specificity. Clin. Exp. Immunol. 2003, 133:370-377.
52. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., Nishijima M. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J. Biol. Chem. 2000, 275:2251-2254.
53. Ando I., Tsukumo Y., Wakabayashi T., Akashi S., Miyake K., Kataoka T., Nagai K. Safflower polysaccharides activate the transcription factor NF-kappa B via Toll-like receptor 4 and induce cytokine production by macrophages. Int. Immunopharmacol. 2002, 2:1155-1162.
54. Okamoto M., Oh-E G., Oshikawa T., Furuichi S., Tano T., Ahmed S.U., Akashi S., Miyake K., Takeuchi O., Akira S., Himeno K., Sato M., Ohkubo S. Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant. Clin. Diagn. Lab. Immunol. 2004, 11:483-495.
55. Tanaka S., Koizumi S., Makiuchi N., Aoyagi Y., Quivy E., Mitamura R., Kano T., Wakita D., Chamoto K., Kitamura H., Nishimura T. The extract of Japanese soybean, Kurosengoku activates the production of IL-12 and IFN-γ by DC or NK1.1(+) cells in a TLR4- and TLR2-dependent manner. Cell. Immunol. 2011, 266:135-142.
56. Bevan M.J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 1976, 143:1283-1288.
57. Bevan M.J. Cross-priming. Nat. Immunol. 2006, 7:363-365.
58. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006, 314:1936-1938.
59. Ishii K.J., Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 2007, 27:363-371.
60. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 2005, 11:S63-68.
61. Khan S., Bijker M.S., Weterings J.J., Tanke H.J., Adema G.J., van Hall T., Drijfhout J.W., Melief C.J., Overkleeft H.S., van der Marel G.A., Filippov D.V., van der Burg S.H., Ossendorp F. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 2007, 282:21145-21159.
62. Wolf N.A., Amouzegar T.K., Swanborg R.H. Synergistic interaction between Toll-like receptor agonists is required for induction of experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 2007, 185:115-122.
63. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J. Exp. Med. 2006, 203:413-424.
64. Chamoto K., Takeshima T., Wakita D., Ohkuri T., Ashino S., Omatsu T., Shirato H., Kitamura H., Togashi Y., Nishimura T. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells. Cancer Sci. 2009, 100:934-939.